U.S. markets closed

Morphic Holding, Inc. (MORF)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
60.29+0.20 (+0.33%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Williams %R

Williams %R

Previous Close60.09
Open60.60
Bid56.00 x 800
Ask72.50 x 1100
Day's Range59.54 - 61.00
52 Week Range22.10 - 93.00
Volume55,397
Avg. Volume213,600
Market Cap2.183B
Beta (5Y Monthly)1.20
PE Ratio (TTM)N/A
EPS (TTM)-1.58
Earnings DateMar 01, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est100.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Hedge Funds Are Crazy About Morphic Holding, Inc. (MORF)
    Insider Monkey

    Hedge Funds Are Crazy About Morphic Holding, Inc. (MORF)

    How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that smart money investors are collectively bullish on. Hedge funds and other institutional investors usually invest large amounts of […]

  • Morphic Therapeutic Shares New Positive MORF-057 Data From IBD Study
    Benzinga

    Morphic Therapeutic Shares New Positive MORF-057 Data From IBD Study

    Morphic Therapeutic (NASDAQ: MORF) has announced additional data from its Phase 1 trial evaluating MORF-057 for inflammatory bowel disease (IBD). The data were shared at the Congress of European Crohn's and Colitis Organization 2021 Virtual Congress. The additional data include detail regarding the safety, pharmacokinetics (PK), and pharmacodynamics (PD) performance of MORF-057 in healthy subjects. MORF-057 was well tolerated in all cohorts, and no safety signals were identified. It demonstrated

  • Morphic Reports New Data from Positive Phase 1 Study of MORF-057, Oral Integrin Inhibitor Candidate for IBD
    GlobeNewswire

    Morphic Reports New Data from Positive Phase 1 Study of MORF-057, Oral Integrin Inhibitor Candidate for IBD

    MORF-057 well tolerated across all phase 1 cohorts Dose-dependent α4β7 receptor occupancy (RO) observed with receptor saturation at 100 mg dose Biomarker changes including lymphocyte subset migration and CCR9 transcript levels provide early proof of biology Conference call today at 8:00 AM ET WALTHAM, Mass., July 09, 2021 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic